CDC panel endorses Moderna vaccine for Americans

As the coronavirus continued to increase in the United States, an independent panel of experts advising the Centers for Disease Control and Prevention voted on Saturday to approve a second coronavirus vaccine for use in the United States.

The committee’s advice follows an emergency permit issued by the Food and Drug Administration on Friday. The committee’s approval is now pending final approval by Dr. Robert R. Redfield, director of the CDC, expected soon.

About 5.9 million doses of the Moderna vaccine are scheduled for distribution as of Sunday, with the first vaccinations expected to begin sometime on Monday.

Unlike the Pfizer BioNTech vaccine, which was approved for use in individuals 16 years of age and older, Moderna’s vaccine is only approved for individuals 18 years of age and older. While Pfizer began clinical trials of its vaccine in children as young as 12 years old in October, Moderna only started its pediatric studies this month and does not expect to have complete safety and efficacy data until sometime next year.

Much of the committee’s deliberations focused on the serious allergic reactions reported in several cases following injections of the Pfizer-BioNTech vaccine, which contains ingredients similar to those in Moderna’s recipe.

Six cases of anaphylaxis have now been documented in the United States and two in Great Britain. Several milder allergic reactions have also occurred. More than 272,000 doses of the Pfizer-BioNTech vaccine have been distributed nationwide since Saturday, according to the CDC.

Allergic reactions to vaccines usually occur at a rate of about one in a million. Dr. Grace Lee, a pediatrician and vaccine expert at Stanford University, noted at the committee meeting that the estimates so far seemed to indicate that the risk of these events associated with the Pfizer-BioNTech vaccine “appears qualitatively higher than for most typical vaccines. . “

Still, she added, “For me personally, it doesn’t necessarily change the risk-benefit ratio of the Covid-19 vaccine at this point.”

Dr. Thomas Clark, an epidemiologist at the CDC, noted that people who experience anaphylaxis after receiving an injection should not receive a second dose. It is still unclear whether an ingredient in Pfizer’s vaccine was the direct cause of the reactions.

Some experts have pointed to polyethylene glycol, or PEG, a chemical found in many pharmaceuticals, including laxatives such as Miralax, which has very rarely been found to cause allergic reactions. Both the Pfizer BioNTech and Moderna vaccines contain PEG, although in slightly different formulations.

Dr. Sarah Mbaeyi, a medical officer with the CDC, said the agency is recommending people who know they have severe allergies to any ingredient in the vaccines not to get injections for now.

People with a history of anaphylaxis with other vaccines or injectable therapies should see their doctor and stay on site for a 30 minute follow-up follow-up in case they start to feel nauseous. (Everyone else – including people who react strongly to other substances like food, pollen, or pet dander, and those with mild allergies of any kind – can leave after 15 minutes.)

Three serious allergic reactions were reported in the Moderna clinical studies, involving more than 30,000 adults, half of whom received a placebo instead of the vaccine. No one was believed to be linked to the vaccine.

At the meeting, experts also expressed concern about four cases of a temporary facial paralysis called Bell’s palsy, three of which occurred in the vaccine group in the Moderna study. (Four cases of Bell’s palsy also occurred in Pfizer’s studies, all in the vaccine group.)

There is no evidence yet that the paralysis is directly associated with either vaccine, and Dr. Jacqueline Miller, a senior vice president at Moderna, said her company continued to monitor vaccine recipients for the side effect.

More than half of the people who received the Moderna vaccine in clinical trials reported uncomfortable symptoms, including fatigue, headache, and pain, after their second injection, about four weeks after the first injection. Some volunteers also developed a fever or a rash around the injection site.

Incidents such as this seem to be much more common with Moderna’s vaccine than Pfizer’s, which contains a smaller dose of the active ingredients. But most of the side effects resolved within a day or so after the vaccination.

Temporary symptoms after vaccination are relatively common. Often times, they are the outward signs of an immune system working hard preparing the body to ward off disease in the future.

Neither Moderna nor Pfizer have collected data on people who are pregnant or breastfeeding to date. But none of the 13 volunteers who became pregnant while participating in Moderna’s clinical studies, six of whom received the vaccine, reported harmful effects.

More than 500 Americans who received a dose of Pfizer vaccine were pregnant at the time of their injection.

Many scientists believe that the coronavirus poses a much greater risk to pregnant or nursing people than the vaccine. Stephanie Langel, an immunologist and virologist at Duke University, was given priority in receiving the vaccine because she is researching the coronavirus. She got her shot on Friday.

“For me it’s just a no-brainer,” she said, due to her frequent exposure to the virus. “It’s about your assessment of risks.”

During the meeting, scientists and clinicians underscored the importance of vaccinations for communities disproportionately affected by the pandemic, including people in prisons.

Experts have repeatedly pointed to the importance of working with representatives of communities of color to reaffirm the safety and efficacy of vaccines for those who are hesitant or skeptical about the shots. (Extremely few people who identified as American Indian, Alaska Native, Native Hawaiian, or Pacific Islander participated in the Moderna trials.)

Dionne Brown, the director of nursing at Summit Rehabilitation and Care Community in Aurora, Colorado, told The New York Times that she was “a little worried about the side effects.” But after lengthy discussions with her colleagues about how safe and effective the vaccines have proven, “I feel comfortable taking them,” she said.

Mrs. Brown, a mother of six, hopes to be an example to her family and community, as well as the other staff and elderly residents of her long-term care facility.

“That’s what my purpose and purpose is,” she said. “That they will see me and hopefully feel comfortable.”

During a second session on Sunday, CDC officials and scientists will provide more advice on how to allocate the newly released vaccines and vote on how to prioritize people to receive vaccinations.

Source